2 days ago
Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented:
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
3 days ago
Gen Zers are kickstarting their careers as AI alters the labor market in real time. And while they may be among the best equipped cohorts to deal with the swift technological change, they're also smart enough to know what they don't know.
Last year, a whopping 86% of Gen Zers said that they crave mentorship from their managers "to offer guidance, support, inspiration, and motivation," according to a Deloitte report.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#last #jeff #americans
Last year, a whopping 86% of Gen Zers said that they crave mentorship from their managers "to offer guidance, support, inspiration, and motivation," according to a Deloitte report.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#last #jeff #americans
10 days ago
HRL claims 60 straight years of annual dividend raises; GIS offers a higher ~6% yield but froze its payout from 2018 through 2020.
GIS generated $2 billion in operating cash flow but posted an $85 million net loss after nearly $3 billion in non-cash impairment charges.
Just released. Our ****** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
Two of the most reliable dividend names in packaged food just wrote fresh checks to shareholders, and the scorecards look nothing alike. Hormel Foods (NYSE:HRL) closed out its 60-year run of annual increases with a quarterly payout that management called its 392nd consecutive quarterly payout. General Mills (NYSE:GIS) delivered a fatter check backed by a 127-year streak of uninterrupted payments, but a fresh round of impairments has investors questioning what comes next.
Here is how the two dividend kings of the grocery aisle stack up right now.
#payout #NYSE #annual #fresh
GIS generated $2 billion in operating cash flow but posted an $85 million net loss after nearly $3 billion in non-cash impairment charges.
Just released. Our ****** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
Two of the most reliable dividend names in packaged food just wrote fresh checks to shareholders, and the scorecards look nothing alike. Hormel Foods (NYSE:HRL) closed out its 60-year run of annual increases with a quarterly payout that management called its 392nd consecutive quarterly payout. General Mills (NYSE:GIS) delivered a fatter check backed by a 127-year streak of uninterrupted payments, but a fresh round of impairments has investors questioning what comes next.
Here is how the two dividend kings of the grocery aisle stack up right now.
#payout #NYSE #annual #fresh
17 days ago
While Wall Street debates AI chip stocks and hyperscaler capital expenditure, a much quieter deployment of the same technology is beginning to change how the physical world gets maintained.
The infrastructure you drive over, walk across, and depend on every day is becoming the next frontier for AI systems.
The United States has roughly 623,000 bridges. Almost half are in fair condition. About 7% are structurally deficient. Roads earned a D+ in the American Society of Civil Engineers' most recent national ****** sment.
The country's infrastructure report card has improved in recent years, but the backlog for bridge rehabilitation alone runs to $373 billion over the next decade.
AI is now being deployed to help close that gap, and the companies doing it are addressing a market that most technology investors are not watching.
#technology #wall #almost
The infrastructure you drive over, walk across, and depend on every day is becoming the next frontier for AI systems.
The United States has roughly 623,000 bridges. Almost half are in fair condition. About 7% are structurally deficient. Roads earned a D+ in the American Society of Civil Engineers' most recent national ****** sment.
The country's infrastructure report card has improved in recent years, but the backlog for bridge rehabilitation alone runs to $373 billion over the next decade.
AI is now being deployed to help close that gap, and the companies doing it are addressing a market that most technology investors are not watching.
#technology #wall #almost
23 days ago
One of the hotter stocks in big healthcare just now is pharmacy chain mainstay CVS Health (NYSE: CVS). The company's shares have raced more than 18% higher year to date, comparing favorably to the benchmark S&P 500 index's sub-13% rise.
And, according to most ****** ysts tracking the stock, the stock's not done yet. According to data compiled by TipRanks, the consensus pundit price target is $114.59 per share, which is 22% above its most recent closing level.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's open the doors of this busy pharmacy to determine how it got here, and whether it can indeed continue to move higher.
Any company that delivers two estimates-crushing quarters in a row is going to be a juicy buy candidate for investors. In all three of the quarterly earnings reports that CVS published this calendar year, it topped consensus ****** yst estimates for revenue and profitability. Investors are more impressed by the latter, naturally, so the company looked particularly good with its convincing beats in both the first and second frames.
#continue #pharmacy
And, according to most ****** ysts tracking the stock, the stock's not done yet. According to data compiled by TipRanks, the consensus pundit price target is $114.59 per share, which is 22% above its most recent closing level.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's open the doors of this busy pharmacy to determine how it got here, and whether it can indeed continue to move higher.
Any company that delivers two estimates-crushing quarters in a row is going to be a juicy buy candidate for investors. In all three of the quarterly earnings reports that CVS published this calendar year, it topped consensus ****** yst estimates for revenue and profitability. Investors are more impressed by the latter, naturally, so the company looked particularly good with its convincing beats in both the first and second frames.
#continue #pharmacy
25 days ago
A Bitcoin (BTCUSD) treasury is only as strong as the financing behind it. That reality is front and center for Strategy (MSTR), formerly MicroStrategy, which has shifted its immediate priority from adding to its Bitcoin reserve toward safeguarding liquidity and managing the obligations attached to its preferred-stock capital structure.
Strategy raised $333.7 million by selling its shares to repurchase Stretch (STRC) preferred and added $149.1 million to its U.S. dollar reserve. Importantly, the company made no Bitcoin purchases or sales during the week, leaving its holdings unchanged at 840,447 BTC.
Barron Trump, 20, Now Worth $150 Million — More Than Mom, Melania — From Crypto And $39 Energy Drink
Billionaire Michael Saylor Warns Against Buying a House Because 'Every 36 Years You Actually Pay the Cost of the House in Tax to the Government'
QQQ Just 'Gamma Flipped' as Market Makers Were Forced to Sell. Here's What Our Top Chart Expert is Tracking Next.
#reserve
Strategy raised $333.7 million by selling its shares to repurchase Stretch (STRC) preferred and added $149.1 million to its U.S. dollar reserve. Importantly, the company made no Bitcoin purchases or sales during the week, leaving its holdings unchanged at 840,447 BTC.
Barron Trump, 20, Now Worth $150 Million — More Than Mom, Melania — From Crypto And $39 Energy Drink
Billionaire Michael Saylor Warns Against Buying a House Because 'Every 36 Years You Actually Pay the Cost of the House in Tax to the Government'
QQQ Just 'Gamma Flipped' as Market Makers Were Forced to Sell. Here's What Our Top Chart Expert is Tracking Next.
#reserve
28 days ago
Archer Aviation (NYSE: ACHR) reported its second-quarter results on Monday, and the two numbers that matter most sit at opposite ends of the release. The air taxi maker expects an adjusted EBITDA loss of $170 million to $200 million for the third quarter. And it closed out June holding $1.56 billion in cash, cash equivalents, and short-term investments.
Set one number against the other and the arithmetic is simple: At the top of that guidance, Archer's money covers roughly two more years of losses. What has to happen inside them?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
After all, this is a company still almost entirely ahead of its revenue. Second-quarter sales were $5 million, mostly from operating Hawthorne Airport in Los Angeles, against a net loss of $263 million.
None of that is surprising for a business building an aircraft program and a defense platform at once. But it does make the balance sheet the number to watch. As of this writing, shares sit near $6.60 after sliding 5% on Friday.
#loss
Set one number against the other and the arithmetic is simple: At the top of that guidance, Archer's money covers roughly two more years of losses. What has to happen inside them?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
After all, this is a company still almost entirely ahead of its revenue. Second-quarter sales were $5 million, mostly from operating Hawthorne Airport in Los Angeles, against a net loss of $263 million.
None of that is surprising for a business building an aircraft program and a defense platform at once. But it does make the balance sheet the number to watch. As of this writing, shares sit near $6.60 after sliding 5% on Friday.
#loss
1 month ago
A fresh tax raid on banks would hurt Britain, the boss of one of Wall Street's biggest banks has warned Andy Burnham.
Dame Jane Fraser, the Scottish-born chief executive of Citigroup investment bank, said that any increase in taxes risked making the UK a prohibitively expensive place to do business.
During a visit to London on Wednesday, she said that "money moves with its feet", pointing out that "even Frankfurt and Paris are lower" when it comes to taxes for banks.
"It makes it a tougher decision. You know, it's already one of the most expensive centres in the world," she added.
Dame Jane signalled that customers may choose to do business elsewhere should the Prime Minister raise taxes on banks.
#jane
Dame Jane Fraser, the Scottish-born chief executive of Citigroup investment bank, said that any increase in taxes risked making the UK a prohibitively expensive place to do business.
During a visit to London on Wednesday, she said that "money moves with its feet", pointing out that "even Frankfurt and Paris are lower" when it comes to taxes for banks.
"It makes it a tougher decision. You know, it's already one of the most expensive centres in the world," she added.
Dame Jane signalled that customers may choose to do business elsewhere should the Prime Minister raise taxes on banks.
#jane
1 month ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted BillionToOne, Inc. (NASDAQ:BLLN). BillionToOne, Inc. (NASDAQ:BLLN), a precision diagnostics company leveraging its technology to quantify biology to create molecular diagnostics, delivered strong performance during the quarter. On August 03, 2026, BillionToOne, Inc. (NASDAQ:BLLN) closed at $137.32 per share. The one-month return of BillionToOne, Inc. (NASDAQ:BLLN) was 16.33%, and YTD its shares gained 67.79% over the past 52 weeks. BillionToOne, Inc. (NASDAQ:BLLN) has a market capitalization of $6.32 billion.
Baron Health Care Fund stated the following regarding BillionToOne, Inc. (NASDAQ:BLLN) in its Q2 2026 investor letter:
"BillionToOne, Inc. (NASDAQ:BLLN) is a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests. Today, the vast majority of the company's revenue is generated by UNITY, a unique prenatal test that can screen for recessive single gene disorders from a maternal blood draw and identify fetal antigen status across both red blood cell and platelet antigens. Shares rose in the second quarter after the company reported robust first-quarter results (revenue up 84% year over year with 22% operating margins) and announced a meaningful expansion of commercial insurance coverage for its UNITY test and new UNITY Confirm product, which can replace amniocentesis or chorionic villus sampling to confirm a genetic diagnosis following a high-risk UNITY screening result. We continue to believe that BillionToOne's differentiated "quantitative counting template" technology enables more sensitive genetic testing. The company is making early headway in oncology with its SELECT therapy selection and RESPONSE therapy monitoring tests, which we think will be important future growth drivers."
#NASDAQ #baron
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted BillionToOne, Inc. (NASDAQ:BLLN). BillionToOne, Inc. (NASDAQ:BLLN), a precision diagnostics company leveraging its technology to quantify biology to create molecular diagnostics, delivered strong performance during the quarter. On August 03, 2026, BillionToOne, Inc. (NASDAQ:BLLN) closed at $137.32 per share. The one-month return of BillionToOne, Inc. (NASDAQ:BLLN) was 16.33%, and YTD its shares gained 67.79% over the past 52 weeks. BillionToOne, Inc. (NASDAQ:BLLN) has a market capitalization of $6.32 billion.
Baron Health Care Fund stated the following regarding BillionToOne, Inc. (NASDAQ:BLLN) in its Q2 2026 investor letter:
"BillionToOne, Inc. (NASDAQ:BLLN) is a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests. Today, the vast majority of the company's revenue is generated by UNITY, a unique prenatal test that can screen for recessive single gene disorders from a maternal blood draw and identify fetal antigen status across both red blood cell and platelet antigens. Shares rose in the second quarter after the company reported robust first-quarter results (revenue up 84% year over year with 22% operating margins) and announced a meaningful expansion of commercial insurance coverage for its UNITY test and new UNITY Confirm product, which can replace amniocentesis or chorionic villus sampling to confirm a genetic diagnosis following a high-risk UNITY screening result. We continue to believe that BillionToOne's differentiated "quantitative counting template" technology enables more sensitive genetic testing. The company is making early headway in oncology with its SELECT therapy selection and RESPONSE therapy monitoring tests, which we think will be important future growth drivers."
#NASDAQ #baron
2 months ago
Freeport-McMoRan Inc. (FCX), headquartered in Phoenix, Arizona, is a leading international metals company with the objective of being foremost in copper. With a market cap of $88.6 billion, the company mines mineral properties exploring copper, gold, molybdenum, silver, and other metals.
Shares of this leading international metals company have outperformed the broader market over the past year. FCX has gained 39% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.3%. In 2026, FCX's stock rose 18.3%, surpassing the SPX's 8.5% rise on a YTD basis.
Dear Sandisk Stock Fans, Mark Your Calendars for August 5
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap
Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock
#company #freeport
Shares of this leading international metals company have outperformed the broader market over the past year. FCX has gained 39% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.3%. In 2026, FCX's stock rose 18.3%, surpassing the SPX's 8.5% rise on a YTD basis.
Dear Sandisk Stock Fans, Mark Your Calendars for August 5
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap
Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock
#company #freeport
2 months ago
Some stock drops look like bad news on the surface. Some are, yes, but some also tell a completely different story underneath.
And I think American Express (AXP) investors have been handed the latter. The payments giant beat earnings expectations, raised its full-year revenue guidance, and reported its strongest card member spending growth in three years. The stock fell anyway.
This kind of reaction can frustrate shareholders and even confuse casual observers. But for "Mad Money" host Jim Cramer, it's a pattern he's seen before, and one he thinks is creating a clear opening.
I think it's a terrific opportunity in one of the best-run companies on earth.
American Express CEO Steve Squeri echoed that confidence in the company's Q2 2026 earnings statement, noting: "Six months into the year, we're seeing stronger momentum than we expected."
#Stock
And I think American Express (AXP) investors have been handed the latter. The payments giant beat earnings expectations, raised its full-year revenue guidance, and reported its strongest card member spending growth in three years. The stock fell anyway.
This kind of reaction can frustrate shareholders and even confuse casual observers. But for "Mad Money" host Jim Cramer, it's a pattern he's seen before, and one he thinks is creating a clear opening.
I think it's a terrific opportunity in one of the best-run companies on earth.
American Express CEO Steve Squeri echoed that confidence in the company's Q2 2026 earnings statement, noting: "Six months into the year, we're seeing stronger momentum than we expected."
#Stock
2 months ago
Any concerns about a slowdown in artificial intelligence (AI) infrastructure spending were put to rest by one of the most important semiconductor companies in the world -- ASML Holding (NASDAQ: ASML) -- when it released its second-quarter results on July 15.
ASML's revenue and earnings blew past Wall Street's expectations. It also raised its full-year guidance. This terrific performance shouldn't come as a surprise considering the Dutch company's critical role in the global semiconductor market. ASML stock, which has already jumped nearly 50% in 2026, is now poised for stronger gains.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's take a look at a simple reason why investors should consider buying this semiconductor stock following its solid Q2 report.
ASML reported Q2 revenue of 9.3 billion euros and net income of 2.92 billion euros. ******* ysts would have settled for net income of 2.62 billion euros on revenue of 8.8 billion euros. However, the booming demand for advanced chipmaking equipment to serve the growing appetite for AI chips deployed in data centers, smartphones, and personal computers (PCs) helped ASML easily crush expectations.
#NVIDIA
ASML's revenue and earnings blew past Wall Street's expectations. It also raised its full-year guidance. This terrific performance shouldn't come as a surprise considering the Dutch company's critical role in the global semiconductor market. ASML stock, which has already jumped nearly 50% in 2026, is now poised for stronger gains.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's take a look at a simple reason why investors should consider buying this semiconductor stock following its solid Q2 report.
ASML reported Q2 revenue of 9.3 billion euros and net income of 2.92 billion euros. ******* ysts would have settled for net income of 2.62 billion euros on revenue of 8.8 billion euros. However, the booming demand for advanced chipmaking equipment to serve the growing appetite for AI chips deployed in data centers, smartphones, and personal computers (PCs) helped ASML easily crush expectations.
#NVIDIA
2 months ago
Alphabet (GOOGL), Meta Platforms (META) and Amazon (AMZN) are each shelling out hundreds of billions to establish themselves as AI winners. ***** ysts at Wedbush Securities say Google and Amazon stocks are better picks in that race than Meta.
Wedbush ***** yst Ygal Arounian ***** umed coverage of the three internet-focused cloud hyperscalers with a new research note for clients Thursday. Google and Amazon were started at outperform ratings, while Meta got a neutral grade.
For Alphabet, the outperform call reflects "our view that Google has built the best-positioned full-stack AI franchise in our coverage," the Wedbush note said. Google was Wedbush's top mega-capitalization pick.
Arounian pointed to Google's wide distribution through its search, Android and YouTube products. That distribution is paired with Google's custom Gemini AI model and a full cloud infrastructure business with custom processors.
"Alphabet has become the clear leader in our view within the AI race offering a full-stack monetization opportunity around its AI spend," Arounian wrote.
Wedbush ***** yst Ygal Arounian ***** umed coverage of the three internet-focused cloud hyperscalers with a new research note for clients Thursday. Google and Amazon were started at outperform ratings, while Meta got a neutral grade.
For Alphabet, the outperform call reflects "our view that Google has built the best-positioned full-stack AI franchise in our coverage," the Wedbush note said. Google was Wedbush's top mega-capitalization pick.
Arounian pointed to Google's wide distribution through its search, Android and YouTube products. That distribution is paired with Google's custom Gemini AI model and a full cloud infrastructure business with custom processors.
"Alphabet has become the clear leader in our view within the AI race offering a full-stack monetization opportunity around its AI spend," Arounian wrote.
